Financial Performance and Outlook - The company is targeting a 12% to 14% non-GAAP EPS CAGR [22, 72, 325, 369]. - The company expects to generate approximately $9 billion in adjusted free cash flow (FCF) [19]. - The company is raising FY25 EPS guidance to $8.15 - $8.20 [22, 311]. - The company provides FY26 EPS guidance for ~13% growth [22, 328]. - The company anticipates generating $10B+ in total adjusted free cash flow over the next 3 years [347]. Segment Performance and Strategy - Pharma segment profit growth is expected to be 8% CAGR [19]. - Other segment profit growth is expected to be 10% CAGR [19]. - Specialty is now over $40B in revenue, growing at a 14% CAGR over the last 3 years [104]. - GMPD delivered $92M of segment profit in FY24, a ~$240M increase over FY23 [278]. - The company is investing over $150M in NPHS over the next three years [53].

Core Insights - Cardinal Health is hosting an Investor Day to discuss growth strategies and long-term financial outlook [2][3] - The company emphasizes its strong foundation and significant future growth opportunities [3] Strategic Updates - Cardinal Health is focusing on expanding its Pharmaceutical and Specialty Solutions, particularly in Specialty and higher-margin businesses [4] - The Specialty Alliance platform will include the recently acquired GI Alliance and the new Urology Alliance [5] - The MSO platforms now support approximately 2,200 providers across 28 states [6] Biopharma Solutions - Continued investments in Biopharma Solutions are announced, with expansions into oncology and other therapeutic areas [7] - The Sonexus™ Access and Patient Support platform is expected to more than double its supported therapies by fiscal year 2028 [7] Pharmaceutical Distribution - The Consumer Health Logistics Center in Ohio is set to be fully operational by July 2025, aimed at increasing capacity and efficiency [8] - Plans for a new forward distribution center with advanced automation technology are underway [9] Financial Guidance - FY25 non-GAAP diluted EPS guidance is raised to $8.15 to $8.20, with preliminary FY26 guidance set at $9.10 to $9.30 [10][18] - Long-term targets for non-GAAP diluted EPS growth are set at 12% to 14% for FY26 to FY28 [20] Capital Deployment - The company plans to invest at least $600 million annually in capital expenditures and anticipates at least $750 million in share repurchases each year for the next three years [21]